Results 301 to 310 of about 4,333,198 (360)

Nanozymes in Reactive Oxygen Species‐Dependent Diseases: From Design and Preclinical Studies to Clinical Translation Prospects

open access: yesSmall Structures, Volume 6, Issue 10, October 2025.
Nanozymes emerge as promising therapeutic agents for reactive oxygen species (ROS)‐dependent diseases, offering advantages over traditional biocatalysts through enhanced stability, tunability, and targeting capabilities. This review explores their mechanisms, design strategies, and clinical progress, emphasizing precision medicine potential.
Lihong Zhou   +8 more
wiley   +1 more source

Hormonal Contraception and Endometrial Thickness in IVF/ICSI Cycles: A Multicentre Historical Cohort Study

open access: yesBJOG: An International Journal of Obstetrics &Gynaecology, Volume 132, Issue 11, Page 1681-1688, October 2025.
ABSTRACT Objective To study the association between previous use of levonorgestrel intrauterine system (LNG‐IUS) and endometrial thickness (EMT) in women undergoing in vitro fertilisation (IVF)/intracytoplasmic sperm injection (ICSI) cycles. Design Multicentre historical cohort study.
Mette Peters Michaelsen   +11 more
wiley   +1 more source

Genetic parameters, genome‐wide associations and potential candidate genes for additive and dominance effects of tail traits in Merinoland sheep based on whole‐genome sequence data in a selection experiment

open access: yesAnimal Genetics, Volume 56, Issue 5, October 2025.
Abstract The aim of this study was an in‐depth genomic analysis for tail length (TL), tail characteristics and body measurements in the Merinoland sheep breed considering whole‐genome sequence data. Genomic analyses included the estimation of genetic parameters and dominance effects, genome‐wide associations for the additive and dominance component ...
Johanna Mainzer   +7 more
wiley   +1 more source

Distinct Suppression of Prednisone on Endometrial Immune Cells in Women With Reproductive Failure

open access: yesAmerican Journal of Reproductive Immunology, Volume 94, Issue 4, October 2025.
ABSTRACT Research Question For women with reproductive failure, prednisone is widely used but remains controversial as a therapy for improving clinical outcomes. This study aimed to investigate the impact of prednisone on various endometrial immune cells.
Lu Chen   +12 more
wiley   +1 more source

S2k-Guideline Non-hormonal Contraception, Part 2: Intrauterine Devices and Sterilization: Guideline of the DGGG, OEGGG and SGGG (S2k-Level, AWMF Registry No. 015 - 095, January 2024).

open access: yesGeburtshilfe Frauenheilkd
Böttcher B   +30 more
europepmc   +1 more source

Role of intra‐individual variation in the detection of thresholds for DFI and for misclassification rates: A retrospective analysis of 14,775 SCSA® tests

open access: yesAndrology, Volume 13, Issue 7, Page 1732-1744, October 2025.
Abstract Background Sperm DNA damage is associated with reduced male fertility after natural conception and intrauterine insemination. However, the impact on in vitro fertilization (IVF) and especially intracytoplasmic sperm injection (ICSI) treatments is still unclear.
Preben Christensen   +6 more
wiley   +1 more source

Inhibition of ROS1 activity with lorlatinib reversibly suppresses fertility in male mice

open access: yesAndrology, Volume 13, Issue 7, Page 1891-1900, October 2025.
Abstract Background Inhibition of sperm maturation in the epididymis is a promising post‐testicular strategy for short‐acting male contraceptives. It has been shown that ROS1, a receptor tyrosine kinase expressed in the epididymis, is essential for epididymal differentiation, sperm maturation, and male fertility in mice.
Yuki Oyama   +9 more
wiley   +1 more source

Placental growth factor before 11 weeks for screening of preterm preeclampsia: The PreMoM study

open access: yesActa Obstetricia et Gynecologica Scandinavica, Volume 104, Issue 10, Page 1897-1906, October 2025.
In this multicenter study including 3448 women with singleton pregnancies in Spain, early placental growth factor (PlGF) measurement (<11 weeks) was compared with standard timing (11–13 weeks) for preterm preeclampsia screening. Early measurements showed no added benefit over models without PlGF.
Rocío López Mármol   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy